{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:17:47Z","timestamp":1789525067778,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ecl.2018.04.014","type":"journal-article","created":{"date-parts":[[2018,7,11]],"date-time":"2018-07-11T01:22:43Z","timestamp":1531272163000},"page":"557-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["New Treatments for the Carcinoid Syndrome"],"prefix":"10.1016","volume":"47","author":[{"given":"Paul Benjamin","family":"Loughrey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony P.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ecl.2018.04.014_bib1","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF01966242","article-title":"Ueber den prim\u00e4ren Krebs des Ileum, nebst Bemerkungen \u00fcber das gleichzeitige Vorkommen von Krebs und Tuberkolose","volume":"111","author":"Lubarsch","year":"1888","journal-title":"Virchows Arch"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.10-2-123","article-title":"Metastatic carcinoid tumors: a clinical review","volume":"10","author":"Zuetenhorst","year":"2005","journal-title":"Oncologist"},{"issue":"12","key":"10.1016\/j.ecl.2018.04.014_bib3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.humpath.2004.09.018","article-title":"Siegfried Oberndorfer: origins and perspectives of carcinoid tumors","volume":"35","author":"Modlin","year":"2004","journal-title":"Hum Pathol"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib4","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1148\/rg.2017160113","article-title":"Multimodality imaging findings in carcinoid tumors: a head-to-toe spectrum","volume":"37","author":"Baxi","year":"2017","journal-title":"Radiographics"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0960-7404(01)00007-X","article-title":"Recent advances in carcinoid pathogenesis, diagnosis and management","volume":"9","author":"Ganim","year":"2000","journal-title":"Surg Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1210\/er.2003-0014","article-title":"The diagnosis and medical management of advanced neuroendocrine tumors","volume":"25","author":"Kaltsas","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ecl.2018.04.014_bib7","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3332\/ecancer.2016.662","article-title":"Complications from carcinoid syndrome: review of the current evidence","volume":"10","author":"Mota","year":"2016","journal-title":"Ecancermedicalscience"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.014_bib8","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors","volume":"340","author":"Kulke","year":"1999","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib9","doi-asserted-by":"crossref","first-page":"534","DOI":"10.4158\/EP14464.DSC","article-title":"AACE\/ACE disease state clinical review: diagnosis and management of midgut carcinoids","volume":"21","author":"Liu","year":"2015","journal-title":"Endocr Pract"},{"issue":"16","key":"10.1016\/j.ecl.2018.04.014_bib10","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.7314\/APJCP.2014.15.16.6679","article-title":"Somatostatin analogues do not prevent carcinoid crisis","volume":"15","author":"Guo","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"Suppl 2","key":"10.1016\/j.ecl.2018.04.014_bib11","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/annonc\/12.suppl_2.S95","article-title":"Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours","volume":"12","author":"Tomassetti","year":"2001","journal-title":"Ann Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2018.04.014_bib12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10555-011-9292-1","article-title":"Current knowledge on diagnosis and staging of neuroendocrine tumors","volume":"30","author":"Oberg","year":"2011","journal-title":"Cancer Metastasis Rev"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib13","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1159\/000085237","article-title":"Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)","volume":"80","author":"Plockinger","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/gutjnl-2011-300831","article-title":"Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)","volume":"61","author":"Ramage","year":"2012","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.surg.2015.05.036","article-title":"Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis","volume":"159","author":"Condron","year":"2016","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","article-title":"Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival","volume":"197","author":"Sarmiento","year":"2003","journal-title":"J\u00a0Am Coll Surg"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib17","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","article-title":"Hepatic resection for metastatic neuroendocrine carcinomas","volume":"169","author":"Que","year":"1995","journal-title":"Am J Surg"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1053\/j.seminoncol.2010.03.004","article-title":"Transarterial liver-directed therapies of neuroendocrine hepatic metastases","volume":"37","author":"Nazario","year":"2010","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib19","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ejrad.2008.08.008","article-title":"Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation","volume":"72","author":"Vogl","year":"2009","journal-title":"Eur J Radiol"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.suronc.2012.07.001","article-title":"Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases - a systematic review","volume":"21","author":"Yang","year":"2012","journal-title":"Surg Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib21","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1007\/s00268-008-9510-3","article-title":"Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors","volume":"32","author":"Eriksson","year":"2008","journal-title":"World J Surg"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib24","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-011-0248-1","article-title":"Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres","volume":"35","author":"Paprottka","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ajco.12438","article-title":"Hepatic artery embolization in advanced neuroendocrine tumors: Efficacy and long-term outcomes","volume":"12","author":"Pericleous","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.014_bib26","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s11605-008-0640-6","article-title":"Hepatic neuroendocrine metastases: chemo- or bland embolization?","volume":"12","author":"Pitt","year":"2008","journal-title":"J\u00a0Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1177\/107327480601300110","article-title":"Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors","volume":"13","author":"Strosberg","year":"2006","journal-title":"Cancer Control"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib28","first-page":"631","article-title":"Intra-arterial treatment with 90yttrium microspheres in treatment-refractory and unresectable liver metastases of neuroendocrine tumors and the use of 111in-octreotide scintigraphy in the evaluation of treatment response","volume":"26","author":"Lacin","year":"2011","journal-title":"Cancer Biother Radiopharm"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ijrobp.2011.07.041","article-title":"Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes","volume":"83","author":"Memon","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000209849","article-title":"Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study","volume":"79","author":"Kalinowski","year":"2009","journal-title":"Digestion"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib31","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1148\/radiol.2372041203","article-title":"Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy","volume":"237","author":"McStay","year":"2005","journal-title":"Radiology"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/j.1477-2574.2011.00405.x","article-title":"Predictors of response to radio-embolization (TheraSphere(R)) treatment of neuroendocrine liver metastasis","volume":"14","author":"Shaheen","year":"2012","journal-title":"HPB (Oxford)"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib33","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/SLA.0b013e3181d3d24a","article-title":"Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases","volume":"251","author":"Saxena","year":"2010","journal-title":"Ann Surg"},{"issue":"20","key":"10.1016\/j.ecl.2018.04.014_bib34","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1301537","article-title":"Ondansetron for diarrhea associated with neuroendocrine tumors","volume":"368","author":"Kiesewetter","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.ecl.2018.04.014_bib35","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0959-8049(98)00009-4","article-title":"Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome","volume":"34","author":"Wymenga","year":"1998","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.014_bib36","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0024-3205(82)90087-X","article-title":"SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action","volume":"31","author":"Bauer","year":"1982","journal-title":"Life Sci"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib37","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-017-0461-5","article-title":"Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract","volume":"18","author":"Cives","year":"2017","journal-title":"Curr Treat Options Oncol"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.014_bib38","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue","volume":"315","author":"Kvols","year":"1986","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib39","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1136\/gut.26.5.438","article-title":"Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses","volume":"26","author":"Wood","year":"1985","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib40","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1677\/erc.1.01200","article-title":"Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma","volume":"13","author":"Butturini","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib41","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2265.2002.01619.x","article-title":"Antiangiogenic effects of somatostatin analogues","volume":"57","author":"Garcia de la Torre","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib42","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.ecl.2018.04.014_bib43","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/annonc\/mdl105","article-title":"Rationale for the use of somatostatin analogs as antitumor agents","volume":"17","author":"Susini","year":"2006","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.1992.65","article-title":"Insulin-like growth factors and cancer","volume":"65","author":"Macaulay","year":"1992","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib45","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#","article-title":"Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors","volume":"79","author":"Trendle","year":"1997","journal-title":"Cancer"},{"issue":"1\u20132","key":"10.1016\/j.ecl.2018.04.014_bib46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"issue":"4 Suppl 1","key":"10.1016\/j.ecl.2018.04.014_bib47","first-page":"134","article-title":"111In-octreotide scintigraphy in metastatic medullary thyroid carcinoma before and after octreotide therapy: in\u00a0vivo evidence of the possible down-regulation of somatostatin receptors","volume":"39","author":"Ronga","year":"1995","journal-title":"Q\u00a0J Nucl Med"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib48","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jss.2004.03.006","article-title":"Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR","volume":"119","author":"Li","year":"2004","journal-title":"J\u00a0Surg Res"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib49","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1634\/theoncologist.2015-0455","article-title":"Inhibition of peripheral synthesis of serotonin as a new target in neuroendocrine tumors","volume":"21","author":"Molina-Cerrillo","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ecl.2018.04.014_bib50","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"10.1016\/j.ecl.2018.04.014_bib51","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1185\/03007990903328959","article-title":"From somatostatin to octreotide LAR: evolution of a somatostatin analogue","volume":"25","author":"Anthony","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib52","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1758834016675803","article-title":"Refractory carcinoid syndrome: a review of treatment options","volume":"9","author":"Riechelmann","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.24.2669","article-title":"Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial","volume":"28","author":"Yao","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"9808","key":"10.1016\/j.ecl.2018.04.014_bib54","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(11)61742-X","article-title":"Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study","volume":"378","author":"Pavel","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib55","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"10022","key":"10.1016\/j.ecl.2018.04.014_bib56","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ecl.2018.04.014_bib57","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1634\/theoncologist.2014-0037","article-title":"Real-world study of everolimus in advanced progressive neuroendocrine tumors","volume":"19","author":"Panzuto","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2559.1998.00321.x","article-title":"Expression of vascular endothelial growth factor in digestive neuroendocrine tumours","volume":"32","author":"Terris","year":"1998","journal-title":"Histopathology"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib59","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"20","key":"10.1016\/j.ecl.2018.04.014_bib60","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1200\/JCO.2007.15.9020","article-title":"Activity of sunitinib in patients with advanced neuroendocrine tumors","volume":"26","author":"Kulke","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib61","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.dld.2011.08.022","article-title":"New treatment strategies in advanced neuroendocrine tumours","volume":"44","author":"Walter","year":"2012","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib62","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11523-012-0224-y","article-title":"Streptozocin-based chemotherapy is not history in neuroendocrine tumours","volume":"7","author":"Weatherstone","year":"2012","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib63","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib65","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1677\/ERC-09-0104","article-title":"Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710","volume":"16","author":"Dahan","year":"2009","journal-title":"Endocr Relat Cancer"},{"issue":"22","key":"10.1016\/j.ecl.2018.04.014_bib66","doi-asserted-by":"crossref","first-page":"4897","DOI":"10.1200\/JCO.2005.03.616","article-title":"Phase II\/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281","volume":"23","author":"Sun","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.014_bib67","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor","volume":"2","author":"Engstrom","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ecl.2018.04.014_bib68","unstructured":"Clinical Trials.gov. Peptide receptor radionuclide therapy with 177Lu-Dotatate associated with metronomic capecitabine in patients affected by aggressive gastro-etero-pancreatic neuroendocrine tumors (LuX). 2017; Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02736500. Accessed December 03, 2017."},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib69","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1089\/jir.2006.26.8","article-title":"Efficacy and tolerability of pegylated IFN-alpha in patients with neuroendocrine gastroenteropancreatic carcinomas","volume":"26","author":"Pavel","year":"2006","journal-title":"J\u00a0Interferon Cytokine Res"},{"issue":"14","key":"10.1016\/j.ecl.2018.04.014_bib70","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","volume":"21","author":"Faiss","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"issue":"8","key":"10.1016\/j.ecl.2018.04.014_bib72","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S1542-3565(05)00481-7","article-title":"Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial","volume":"3","author":"Arnold","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.ecl.2018.04.014_bib73","doi-asserted-by":"crossref","first-page":"R423","DOI":"10.1530\/ERC-16-0200","article-title":"Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours","volume":"23","author":"Dimitriadis","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib74","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2018.04.014_bib75","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1159\/000080741","article-title":"Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors","volume":"80","author":"Schmid","year":"2004","journal-title":"Neuroendocrinology"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.014_bib76","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A\u00a012-month phase 3 study of pasireotide in Cushing's disease","volume":"366","author":"Colao","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib77","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib78","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.014_bib79","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2002-220219","article-title":"SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone\/insulin-like growth factor-I axis in rats, primates, and dogs","volume":"143","author":"Weckbecker","year":"2002","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-14-0360","article-title":"Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors","volume":"22","author":"Cives","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib81","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib82","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s00018-007-7377-3","article-title":"Role of serotonin in the hepato-gastroIntestinal tract: an old molecule for new perspectives","volume":"65","author":"Lesurtel","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib83","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2014-2247","article-title":"Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial","volume":"100","author":"Pavel","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib84","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1200\/JCO.2016.69.2780","article-title":"Telotristat Ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome","volume":"35","author":"Kulke","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"21","key":"10.1016\/j.ecl.2018.04.014_bib85","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJM196711232772101","article-title":"Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome","volume":"277","author":"Engelman","year":"1967","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib86","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.ecl.2018.04.014_bib87","first-page":"304","article-title":"Pharmaceutical approval update","volume":"42","author":"Choy","year":"2017","journal-title":"P\u00a0T"},{"key":"10.1016\/j.ecl.2018.04.014_bib88","unstructured":"Clinical Trials.gov. Telotristat etiprate for carcinoid syndrome therapy (TELECAST). 2017. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02063659?term=NCT02063659&rank=1. Accessed December 03, 2017."},{"key":"10.1016\/j.ecl.2018.04.014_bib89","unstructured":"Clinical Trials.gov. Telotristat etiprate - expanded treatment for patients with carcinoid syndrome symptoms (TELEPATH). 2017. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02026063. Accessed 12\/03, 2017."},{"issue":"14","key":"10.1016\/j.ecl.2018.04.014_bib90","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","article-title":"Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumors","volume":"33","author":"Hobday","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"issue":"8","key":"10.1016\/j.ecl.2018.04.014_bib91","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.ecl.2018.04.014_bib92","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Phase III prospective randomized comparison trial of depot octreotide plus interferon Alfa-2b versus depot octreotide plus bevacizumab in patients with advanced carcinoid tumors: SWOG S0518","volume":"35","author":"Yao","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.014_bib93","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s002590050314","article-title":"Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours","volume":"25","author":"Chiti","year":"1998","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.014_bib94","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s002680010213","article-title":"Nuclear medicine applications for neuroendocrine tumors","volume":"24","author":"Chatal","year":"2000","journal-title":"World J Surg"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib95","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.semnuclmed.2006.03.007","article-title":"Imaging of neuroendocrine tumors","volume":"36","author":"Rufini","year":"2006","journal-title":"Semin Nucl Med"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib96","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography","volume":"90","author":"Orlefors","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib97","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2967\/jnumed.106.035667","article-title":"68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT","volume":"48","author":"Gabriel","year":"2007","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.ecl.2018.04.014_bib98","article-title":"Therapy-related hematological malignancies after peptide receptor radionuclide therapy with 177Lu-DOTA-Octreotate: incidence, course & predicting factors in patients with GEP-NETs","author":"Bergsma","year":"2017","journal-title":"J\u00a0Nucl Med"},{"issue":"13","key":"10.1016\/j.ecl.2018.04.014_bib99","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","article-title":"Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival","volume":"26","author":"Kwekkeboom","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.beem.2015.10.005","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumours","volume":"30","author":"Brabander","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin Nucl Med"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2018.04.014_bib102","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1007\/s00259-011-2039-y","article-title":"Lutetium-labelled peptides for therapy of neuroendocrine tumours","volume":"39","author":"Kam","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib103","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-14-0488","article-title":"GEPNETs update: radionuclide therapy in neuroendocrine tumors","volume":"172","author":"van der Zwan","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib104","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2018.04.014_bib105","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib106","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00259-002-1023-y","article-title":"Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study","volume":"30","author":"Bodei","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.014_bib107","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2009.22.8585","article-title":"90Y-edotreotide for metastatic carcinoid refractory to octreotide","volume":"28","author":"Bushnell","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1B","key":"10.1016\/j.ecl.2018.04.014_bib108","first-page":"703","article-title":"Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors","volume":"26","author":"Forrer","year":"2006","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib109","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.semnuclmed.2006.01.001","article-title":"Survival and response after peptide receptor radionuclide therapy with [90Y-DOTA0,Tyr3]octreotide in patients with advanced gastroenteropancreatic neuroendocrine tumors","volume":"36","author":"Valkema","year":"2006","journal-title":"Semin Nucl Med"},{"issue":"17","key":"10.1016\/j.ecl.2018.04.014_bib110","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1200\/JCO.2010.33.7873","article-title":"Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers","volume":"29","author":"Imhof","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.ecl.2018.04.014_bib111","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.014_bib112","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2017.1354984","article-title":"The safety of available treatments options for neuroendocrine tumors","volume":"16","author":"Faggiano","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"10.1016\/j.ecl.2018.04.014_bib113","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","article-title":"Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors","volume":"35","author":"Bodei","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.ecl.2018.04.014_bib114","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.clon.2011.12.003","article-title":"Radionuclide therapy in neuroendocrine tumours: a systematic review","volume":"24","author":"Gulenchyn","year":"2012","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib115","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1159\/000324096","article-title":"Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland","volume":"93","author":"Pfeifer","year":"2011","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib116","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.dld.2009.08.004","article-title":"Acute leukaemia following low dose peptide receptor radionuclide therapy for an intestinal carcinoid","volume":"42","author":"Merola","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"6","key":"10.1016\/j.ecl.2018.04.014_bib117","first-page":"659","article-title":"Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC","volume":"24","author":"Sierra","year":"2009","journal-title":"Cancer Biother Radiopharm"},{"issue":"12","key":"10.1016\/j.ecl.2018.04.014_bib118","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","article-title":"Peptide receptor radionuclide therapy with (1)(7)(7)Lu-DOTATATE: the IEO phase I-II study","volume":"38","author":"Bodei","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.ecl.2018.04.014_bib119","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.diii.2013.07.006","article-title":"Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?","volume":"95","author":"Oksuz","year":"2014","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.ecl.2018.04.014_bib120","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00001503-200306000-00017","article-title":"Carcinoid tumor and carcinoid syndrome","volume":"16","author":"Dierdorf","year":"2003","journal-title":"Curr Opin Anaesthesiol"},{"key":"10.1016\/j.ecl.2018.04.014_bib121","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1399-6576.2007.01313.x","article-title":"Scandinavian clinical practice guidelines on the diagnosis, management and follow-up of anaphylaxis during anaesthesia","volume":"51","author":"Kroigaard","year":"2007","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.ecl.2018.04.014_bib122","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/jso.23323","article-title":"Pommier R Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients","volume":"107","author":"Massimino","year":"2013","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ecl.2018.04.014_bib123","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0000000000000850","article-title":"Consensus guidelines for the management and treatment of neuroendocrine tumors","volume":"46","author":"Strosberg","year":"2017","journal-title":"Pancreas"},{"key":"10.1016\/j.ecl.2018.04.014_bib124","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/bja\/87.3.447","article-title":"Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours","volume":"87","author":"Kinney","year":"2001","journal-title":"Br J Anaesth"},{"issue":"8","key":"10.1016\/j.ecl.2018.04.014_bib125","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1158\/1078-0432.CCR-06-2532","article-title":"A\u00a0novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy","volume":"13","author":"Leja","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ecl.2018.04.014_bib126","doi-asserted-by":"crossref","first-page":"e8916","DOI":"10.1371\/journal.pone.0008916","article-title":"Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability","volume":"5","author":"Leja","year":"2010","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ecl.2018.04.014_bib127","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/gt.2011.54","article-title":"Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells","volume":"18","author":"Leja","year":"2011","journal-title":"Gene Ther"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852918305267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:43:30Z","timestamp":1760175810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852918305267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0889852918305267"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.014","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New Treatments for the Carcinoid Syndrome","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2018.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}